Alvotech SA

Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines through its subsidiaries. The firm's pipeline contains biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. The company was founded on August 23, 2021 and is headquartered in Luxembourg.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alvotech reports robust Q1 earnings, eyes biosimilar market leadership

Alvotech's Q1 2024 earnings call highlighted strong financial performance, progress in commercializing biosimilars, and a positive outlook for revenue growth in 2024. The company's focus on interchangeability, exclusive agreements, and expanding its product pipeline positions it well for future success in the biosimilars market.

Alvotech reports stellar revenue growth and strategic financing moves

Alvotech's strong financial performance, focus on biosimilars, and strategic financing decisions underscore its growth trajectory. Challenges in maintaining margins and meeting EBITDA targets exist, but opportunities from new applications and revenue mix diversification are promising.

Alvotech reports robust Q3 earnings, eyes growth amid profitability challenges

Alvotech's Q3 2024 earnings call showcased strong financial performance, with total revenues reaching $339 million for the first 9 months.
The company reported positive operating profit and adjusted EBITDA for the second consecutive quarter, driven by product revenue growth and margin improvement.
Guidance for 2024 revenue remains at $400 million to $500 million, with a focus on operational execution and maximizing launches for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji”), has received marketing approval for AVT04 (ustekinumab), a biosimilar to Stelara®, from the Japanese Ministry of Health, Labor and Welfare. Based on publicly available information, AVT04 is the first biosimilar to Stelara to be approved for sale in global markets. Global sales of Stelara reached over $10 billion for the twelve months preceding June 30, 2023, according to the manufacturer's public filings, making it one of the world's highest grossing biologics.

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has accepted Alvotech's resubmitted Biologics License Application (BLA) for AVT02, a high-concentration, interchangeable biosimilar candidate to Humira® (adalimumab). The FDA has also announced a Biosimilar User Fee Act (BsUFA) goal date for approval of the resubmitted AVT02 BLA.

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 11–13, 2023.

Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

REYKJAVIK, Iceland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech's Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech's proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).

Alvotech Announces Changes to the Leadership Team

Alvotech (NASDAQ:ALVO ) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET Company Participants Benedikt Stefansson - Director of IR & Global Communications Robert Wessman - Chairman & CEO Anil Okay - Chief Commercial Officer Joel Morales - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Thibault Boutherin - Morgan Stanley Niall Alexander - Deutsche Bank Andrew Baum - Citi Operator Welcome to the Second Quarter 2023 Earnings Call for Alvotech. At this time, all participants are in listen-only mode.

Alvotech (ALVO) Q2 2023 Earnings Call Transcript

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure - Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months of 2023, after U.S. markets close on Wednesday, August 30, 2023.

Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement, in an overseas directed offering directed solely into Iceland to professional clients or eligible counterparties, of subordinated convertible bonds denominated in Icelandic krona (ISK) and US dollar (the “Bonds”) for a par value of $100 million. Alvotech expects to use the proceeds for continued development of its biosimilars pipeline.

Alvotech Completes $100 Million Convertible Bond Private Placement

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

Teva Pharmaceutical

Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market.

Teva Pharmaceuticals and Alvotech expand biosimilars partnership

TEL AVIV, Israel & PARSIPPANY, NJ & REYKJAVIK, Iceland--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have agreed to expand their existing strategic partnership agreement. Teva will also acquir.

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alvotech SA ("Alvotech" or the "Company") (NASDAQ: ALVO). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech SA - ALVO

LOS ANGELES, CA / ACCESSWIRE / July 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ: ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Alvotech specializes in biosimilar medicines. The company received a complete response letter from the FDA regarding the manufacturing facility for its Humira biosimilar, AVT02.

Why Shares of Alvotech Are Jumping Friday

REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's second Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). As the second of two BLAs submitted for AVT02, this BLA contained data to support approval as a high-concentration biosimilar and additional information to support the interchangeability designation.

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

NEW YORK , June 14, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO, ALVOW) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ALVO, ALVOW INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO, ALVOW

Johnson & Johnson

REYKJAVIK, Iceland & TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced they have reached a settlement and license agreement with Johnson & Johnson (NYSE:JNJ) concerning AVT04, Alvotech's proposed biosimilar to Stelara®.

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Alvotech has a resolvable CRL. This took down the stock, but when resolved, that could create a quick spike. Ordinarily, this would be an opportunity, except for Alvotech's poor cash position.

News for Alvotech SA Stock (ALVO)